265. Lipodystrophy
109 clinical trials,   164 drugs   (DrugBank: 59 drugs),   26 drug target genes,   94 drug target pathways

Searched query = "Lipodystrophy", "Berardinelli-Seip syndrome", "Lawrence syndrome", "Barraquer-Simons syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01612858
(ClinicalTrials.gov)
June 20114/6/2012Metabolic Abnormalities in HIV-infected PersonsMetabolic Abnormalities in HIV-infected PersonsLipodystrophy;HIV InfectionDrug: Metformin;Drug: PioglitazoneTufts Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed18 Years70 YearsAll20Phase 4United States
2NCT01023620
(ClinicalTrials.gov)
October 200930/11/2009HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)Human Immunodeficiency Virus Acquired Lipodystrophy (HAL) Classification, Measurement, & Fat Response to a Thiazolidinedione (TZD) Challenge in Differing Adult Phenotypic PresentationsHIV InfectionsDrug: Pioglitazone;Other: ObservationUniversity of Texas Southwestern Medical CenterTakeda Pharmaceuticals North America, Inc.Completed18 YearsN/AMale4N/AUnited States
3NCT00362440
(ClinicalTrials.gov)
August 20069/8/2006Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic SyndromeA Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome: A Randomized, Double-blind, Placebo-controlled Clinical TrialHIV LipodystrophyDrug: Leptin;Drug: Pioglitazone or metformin;Drug: PlaceboBeth Israel Deaconess Medical CenterAmerican Diabetes AssociationCompleted18 YearsN/AAll9Phase 2United States
4NCT00656851
(ClinicalTrials.gov)
September 200510/4/2008Myocardial Function & FFA Metabolism in HIV Metabolic SyndromeMyocardial Function, Free Fatty Acid and Glucose Metabolism in HIV Metabolic SyndromeHIV Infections;Cardiovascular Disease;Insulin Resistance;HIV Lipodystrophy;The Metabolic SyndromeDrug: Pioglitazone;Behavioral: Exercise TrainingNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLCompleted28 Years50 YearsAll24N/AUnited States
5NCT00639457
(ClinicalTrials.gov)
January 200518/3/2008Exercise and Pioglitazone for HIV-Metabolic SyndromesExercise and Pioglitazone for HIV-Metabolic SyndromesHIV Infections;Type 2 Diabetes;Obesity;HIV;AIDS;Cardiovascular Disease;LipodystrophyDrug: Pioglitazone;Behavioral: Exercise trainingNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLCompleted18 Years65 YearsAll44N/AUnited States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00148850
(ClinicalTrials.gov)
February 20037/9/2005Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 PatientsA Randomized, Phase 3, Double Blind, Multicentre Trial, Evaluating the Effect of Pioglitazone Versus Placebo on Change in Lipoatrophy in HIV- 1 Infected Patients Treated With Stable Antiretroviral Therapy for at Least 6 Months.ANRS 113 LIPIOT StudyHIV-Associated Lipodystrophy Syndrome;HIV InfectionsDrug: PioglitazoneFrench National Agency for Research on AIDS and Viral HepatitisTakedaTerminated18 YearsN/ABoth130Phase 3France